AAV market to reach $6.65B by 2030 on gene therapy demand

The adeno-associated viral vectors market is projected to climb from $3.17 billion in 2025 to $6.65 billion by 2030 as gene therapy activity expands worldwide. North America led the market in 2025, while Asia-Pacific is expected to post the fastest growth.

Why it matters: - Adeno-associated viral vectors are a core delivery platform for gene therapy, so rising demand points to broader momentum in treatments for genetic disorders and other diseases. - The market’s growth reflects more research, more clinical programs and more commercial gene therapy launches.

What happened: - The Business Research Company said the global adeno-associated viral vectors market was valued at $3.17 billion in 2025. - The market is projected to reach $3.72 billion in 2026, a 17.6% CAGR. - The forecast puts the market at $6.65 billion by 2030, growing at a 15.6% CAGR. - The company released its Adeno-Associated Viral Vectors Global Market Report 2026, which covers market size, trends and forecasts through 2035.

The details: - Early growth came from initial AAV platform development, limited use in rare diseases, early gene therapy regulations, more research into genetic disorder treatments and higher preclinical investment. - The report points to capsid engineering, improved vector design and more commercial gene therapy product launches as key growth drivers ahead. - Other demand catalysts include personalized medicine, broader global clinical trials and more biotech-pharma partnerships. - The report highlights rising use of AAV-based gene therapies for rare genetic conditions. - It also cites more funding for in vivo and ex vivo gene delivery, wider adoption of AAV vectors in immunotherapy, stronger focus on clinical and commercial-scale gene therapy initiatives, and tighter regulatory oversight with greater product standardization. - AAV vectors are engineered from small, non-pathogenic viruses to deliver therapeutic genes into specific cells. - The vectors are used in gene therapy for genetic disorders, cancers and other conditions. - Their safety profile and ability to infect dividing and non-dividing cells make them useful in research and clinical settings. - Rising genetic disorder incidence is a major market driver. - The report links that growth to advances in diagnostics, greater awareness, older maternal age, environmental factors and genetic variation. - The release cites World Health Organization data from February 2023 showing congenital diseases cause about 240,000 newborn deaths globally in the first 28 days of life each year and 170,000 deaths among children ages 1 month to 5 years. - North America held the largest market share in 2025. - Asia-Pacific is expected to grow the fastest over the coming years. - The analysis also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The company says its 2026 market reports include market attractiveness scoring, TAM analysis, company scoring matrices, Excel-based forecasting dashboards, market hotspots infographics, and updated graphics and tables. - The release included a sample request link: Download a free sample.

Between the lines: - The forecast suggests gene therapy is moving from a research-heavy niche toward a more commercial phase. - Faster growth in Asia-Pacific likely reflects expanding healthcare infrastructure and broader adoption of gene therapies. - The emphasis on standardization and regulatory oversight suggests the market is becoming more mature as safety and manufacturing scale become more important.

What's next: - The market will likely be shaped by more gene therapy launches, larger clinical trials and continued improvements in vector engineering. - Biotech and pharmaceutical collaborations are likely to remain central to commercialization. - Demand should continue rising as genetic disease detection improves and more therapies move toward approval and scaling.

The bottom line: - AAV vectors are moving deeper into mainstream gene therapy, and the market outlook points to sustained double-digit growth through 2030.